Actuate Therapeutics, Inc.

We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (“GSK-3”). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta (“GSK-3β”), a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3β signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. There are no approved high-affinity inhibitors of GSK-3β, and we believe elraglusib is one of the most advanced GSK-3β inhibitors in clinical development.

Current securities

1. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingOct 30, 2026
2. 4 filingOct 29, 2026
3. Entry into a Material Definitive Agreement · Other EventsOct 28, 2026
4. 424B5 filingOct 28, 2026
5. EFFECT filingOct 26, 2026